| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_ITCH_0019100 | Exon-Exon | chr20:33030013-33080402 | chr20:34442208-34492597 | 1547 nt | 0.4124 |
| hsa_ITCH_0019800 | Exon-Exon | chr20:33033092-33099197 | chr20:34445287-34511392 | 250 nt | 0.3440 |
| hsa_ITCH_0021500 | Exon-Exon | chr20:33045195-33057925 | chr20:34457390-34470120 | 287 nt | 0.4355 |
| hsa_ITCH_0021600 | Exon-Exon | chr20:33045195-33059320 | chr20:34457390-34471515 | 359 nt | 0.4290 |
| hsa_ITCH_0021700 | Exon-Exon | chr20:33045195-33069011 | chr20:34457390-34481206 | 883 nt | 0.3964 |
| hsa_ITCH_0021800 | Exon-Exon | chr20:33045195-33080402 | chr20:34457390-34492597 | 1206 nt | 0.3988 |
| hsa_ITCH_0021900 | Exon-Exon | chr20:33045195-33095713 | chr20:34457390-34507908 | 1493 nt | 0.4019 |
| hsa_ITCH_0022900 | Exon-Exon | chr20:33049898-33057925 | chr20:34462093-34470120 | 202 nt | 0.4307 |
| hsa_ITCH_0023000 | Exon-Exon | chr20:33049898-33092208 | chr20:34462093-34504403 | 1194 nt | 0.3970 |
| hsa_ITCH_0024000 | Exon-Exon | chr20:33057853-33059320 | chr20:34470048-34471515 | 145 nt | 0.4345 |
A review consolidating research in humans and model organisms indicates that the circITCH functions as a tumor suppressor in glioma by sponging miR-214 to allow expression of ubiquitin-protein ligase E3, thereby suppressing proliferation and preventing apoptosis, while also targeting the Wnt/β-catenin pathway [Mehta et al. DOI:10.1016/j.pneurobio.2020.101746]. In oesophageal squamous cell carcinoma, the circITCH is downregulated and increases ITCH expression to inhibit the Wnt/β-catenin pathway [Lee et al. DOI:10.1016/j.biopha.2018.12.052]. circITCH hsa_circ_0001141 (circITCH) was found to be lower in the hearts of cancer patients suffering from doxorubicin-induced cardiomyopathy compared to those with dilated cardiomyopathy, hypertrophic cardiomyopathy, and healthy donors, and its expression ameliorates doxorubicin-induced cardiomyocyte injury [Tian et al. DOI:10.3390/molecules26041155].